BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE and RENAL IMPAIRMENT

Overview

RENAL IMPAIRMENT is the #17 most commonly reported adverse reaction for BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE, manufactured by Gilead Sciences, Inc.. There are 799 FDA adverse event reports linking BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE to RENAL IMPAIRMENT. This represents approximately 1.3% of all 62,897 adverse event reports for this drug.

Patients taking BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE who experience renal impairment should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

RENAL IMPAIRMENT is a less commonly reported adverse event for BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE, but still significant enough to appear in the safety profile.

Other Side Effects of BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE

In addition to renal impairment, the following adverse reactions have been reported for BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE:

• BONE DENSITY DECREASED — 6,535 reports
• CHRONIC KIDNEY DISEASE — 3,595 reports
• BONE LOSS — 3,431 reports
• TOOTH LOSS — 3,376 reports
• OSTEONECROSIS — 3,353 reports
• MULTIPLE FRACTURES — 3,121 reports
• RENAL FAILURE — 2,982 reports
• OSTEOPOROSIS — 2,751 reports
• PAIN — 2,531 reports
• RENAL INJURY — 2,478 reports

Other Drugs Associated with RENAL IMPAIRMENT

The following drugs have also been linked to renal impairment in FDA adverse event reports:

Does BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE cause RENAL IMPAIRMENT?

RENAL IMPAIRMENT has been reported as an adverse event in 799 FDA reports for BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is RENAL IMPAIRMENT with BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE?

RENAL IMPAIRMENT accounts for approximately 1.3% of all adverse event reports for BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE, making it a notable side effect.

What should I do if I experience RENAL IMPAIRMENT while taking BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE?

If you experience renal impairment while taking BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages